University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
NCT Number: NCT06521736
The goal of this clinical trial is to evaluate the commercial readiness of an Augmentative and Alternative Communication Brain-Computer Interface (AAC-BCI) device for people with minimal movement who benefit from expressive communication technology. Our clinical trial focuses on up to 8 AAC-BCI users but involves a team of support participants with different roles: an industry partner's consultant, a speech language pathologist (SLP), and the user's in-home support person. Patient and team reported outcome measures data will be collected on usage, performance, reliability and comfort along with performance data of using the AAC-BCI device in the home.
Looking for future studies?
Notify Me14 year and older
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15260, United States
Our clinical trial focuses on 8 Alternative Communication Brain-Computer Interface (AAC-BCI) users but involves a team of support participants with different roles: an industry partner's consultant, a speech language pathologist (SLP) and the user's in-home support person. The AAC-BCI user and support person will be recruited from the SLP's clinic and screened to confirm that the individuals meet the inclusion and exclusion criteria before enrollment. The investigators intend to recruit users with a perceived need for Brain-Computer Interface (BCI) access, ex: eye gaze access is deteriorating, unable to determine another access method. The investigators expect that our user participants will be in late-stage amyotrophic lateral sclerosis (ALS), diagnosed with a brainstem stroke, other degenerative neurologic disorder such as Kennedy disease, or have severe quadriplegic cerebral palsy. The support person will be screened to ensure they are comfortable with technology, learning innovative technology and are available to set-up the AAC-BCI daily at the user's request. The home must have internet. A total of 8 enrolled users means that the investigators will have up to 16 team members supported by a consultant. All clinical trial activity will occur in the home. Once consented and enrolled, the first training session with set-up and calibration will occur with the SLP and PRC consultant. The support person must be present. A second training session with a calibration check and use and training on electroencephalogram (EEG) and logfile data collection will occur within one week. The following baseline data will be collected by the consultant and SLP: 1) A functional rating scale; 2) copy spell task (15 minutes); 3) free spell task (15 minutes); National Aeronautics and Space Administration (NASA) Task Load Index (TLX).
The roles of the team members are as follows:
At the end of the 6-month study, participants will complete a Qualtrics survey to rate the overall commercial readiness of the AAC-BCI device along with rating the AAC-BCI device on satisfaction, performance, reliability, and comfort.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For augmentative and alternative communication, brain-computer interface (AAC-BCI) Users:
For Support Persons
For PRC Regional Consultants
For Clinicians:
Exclusion criteria
For Support Persons:
--Does not speak English
For PRC Regional Consultants:
For Clinicians:
Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
Time frame: 6 months
Stakeholder participants agree "yes" that the Alternative Communication Brain-Computer Interface (AAC-BCI) system is ready for product release with an average combined agreement of 70% on a binary yes/no scale.
Time frame: 6 months
Participants rate degree of satisfaction associated with use of the Alternative Communication Brain-Computer Interface (AAC-BCI) system for communication using a five-point Likert Scale where 1= Very Dissatisfied, 2= Dissatisfied, 3= Neither Satisfied or Dissatisfied, 4= Satisfied, and 5= Very Satisfied; 1-3 is a negative outcome, and 4-5 are a positive outcome.
Time frame: 6 months
Participants rate degree of satisfaction with the overall performance of the Alternative Communication Brain-Computer Interface (AAC-BCI) system during communication using a five-point Likert Scale where 1= Very Dissatisfied, 2= Dissatisfied, 3= Neither Satisfied or Dissatisfied, 4= Satisfied, and 5= Very Satisfied; 1-3 is a negative outcome, and 4-5 are a positive outcome.
Time frame: 6 months
Participants rate degree of satisfaction with the overall reliability of the Alternative Communication Brain-Computer Interface (AAC-BCI) system features and functions during daily use using a five-point Likert Scale where 1= Very Dissatisfied, 2= Dissatisfied, 3= Neither Satisfied or Dissatisfied, 4= Satisfied, and 5= Very Satisfied; 1-3 is a negative outcome, and 4-5 are a positive outcome.
Time frame: 6 months
Participant rate degree of satisfaction with the overall comfort of using the Alternative Communication Brain-Computer Interface (AAC-BCI) system during daily use using a five-point Likert Scale where 1= Very Dissatisfied, 2= Dissatisfied, 3= Neither Satisfied or Dissatisfied, 4= Satisfied, and 5= Very Satisfied; 1-3 is a negative outcome, and 4-5 are a positive outcome.
Kendrea Garand
Other
Compatibility Between Brain-Computer Interface and High Efficiency Augmentative and Alternative Communication Systems: Commercial Readiness
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07429695
Behavior, Communication
View Trial DetailsNCT05318976
Alzheimer Disease, Brain Diseases
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT06828705
Nervous System Diseases, Neurodegenerative Diseases
Vandœuvre-lès-Nancy, France
View Trial DetailsNCT07664865
Brain Diseases, Central Nervous System Diseases
Pavia, Italy
View Trial Details